Skip to content

Inspection Record

L' Oreal Usa, Inc. — FDA 483 Findings

US FDAInspected 2026-04-01Published 2026-10-26 3 findingsQuality unit oversightMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing.

2Material and supplier control

Labels and other labeling materials are not stored separately with suitable identification for each different drug product, strength, dosage form or quantity of contents.

3Material and supplier control

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components, drug product containers, closures and labeling before disposition.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

L' Oreal Usa, Inc. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.